EQS-News: Temedica and Roche extend successful partnership and celebrate milestones with digital patient companions

 

PRESS RELEASE

 

Temedica and Roche extend successful partnership and celebrate milestones with digital patient companions

 

• The successful collaboration between Temedica and Roche continues.
• A five-figure number of patients have benefited from digital companion apps so far.
• Innovative partnership as a key to improving patient care.

 

Munich, October 24, 2024 – Temedica, a leading health insights company based in Munich, and Roche announce the continuation and expansion of their successful long-standing partnership. Together, the two companies have already launched two digital patient companion apps. These include Retinora, developed for individuals with wet age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), and Brisa, a digital companion for people with multiple sclerosis. The Brisa collaboration is celebrating its fifth anniversary this year and will be extended due to its significant success. The “OcreKompass” project, a dedicated service for Ocrevus patients within Brisa, will also be expanded.

 

Since the initiative's launch, a five-figure number of patients have benefited from the apps. Numerous scientific studies have confirmed the value of using digital companions in improving patients' quality of life and medical care. The close collaboration between Temedica and Roche demonstrates how innovative partnerships can significantly enhance patient care.

 

Retinora and Brisa are built on Temedica's unique app platform technology, which is continuously developed to meet the specific needs of patients. The platform ensures scalability, compliance, and incorporates cutting-edge modules to support users.

 

Through integration with Temedica’s Real-World Evidence platform Permea, users of the digital companions regularly receive valuable insights generated from current research findings, and the aggregation and analysis of diverse data sources. Additionally, users can share their experiences for scientific research, actively contributing to the improvement of patient care. All data is handled in strict compliance with the General Data Protection Regulation (GDPR) and with the explicit consent of the users.

 

Prof. Dr. med. Tjalf Ziemssen, Head of the Center for Clinical Neurosciences and Professor of Clinical Neurosciences at the University Hospital of Dresden, emphasizes:

 

“Temedica and Roche’s digital companion apps are a crucial tool in empowering patients to manage their conditions and in utilizing Real-World Data to improve the standard of care. I am particularly familiar with the Brisa app and, based on the data, I can see the positive impact it has on patients' lives.”

 

Gloria Seibert, Founder and CEO of Temedica, and Maira Trauzettel, Integrated Strategy Lead Neuroimmunology at Roche Pharma AG, state:

“The extension of our partnership sends a strong signal for growth and innovation in the digital health landscape. By combining technological expertise and scientific research, we offer comprehensive, personalized support that puts patients' well-being and the improvement of their care at the forefront. We are excited to continue.”

 

With the continuation of their collaboration, Temedica and Roche reaffirm their shared commitment to making significant strides in healthcare.

 

 

About Temedica GmbH
 

Temedica is a health insights company based in Munich. Since 2016, Temedica has operated Europe’s leading Real-World Insights ecosystem in healthcare. Temedica's mission is to enable personalized and individualized medicine, putting patients' needs at the center. This is achieved through the linkage of health-relevant data from various sources, which are processed into valuable insights in compliance with GDPR. Temedica is supported by renowned investors with long-standing experience in the biopharmaceutical industry.

 

About Roche in Germany

Roche employs around 18,250 people in Germany across its Pharma and Diagnostics divisions. The company operates at major sites in Grenzach-Wyhlen (Roche Pharma AG), Mannheim (Roche Diagnostics GmbH, Roche Diagnostics Deutschland GmbH, Roche Diabetes Care GmbH, and Roche Diabetes Care Deutschland GmbH), and Penzberg (Biotechnology Center, Roche Diagnostics GmbH). Roche’s focus spans the entire value chain of its two business areas, “Pharma” and “Diagnostics,” from research and development to production, logistics, marketing, and sales. Each site undertakes global responsibilities in addition to its operations in Germany. Roche has invested more than €5.5 billion in its German locations over the past ten years. In 2023, Roche globally invested 13.2 billion Swiss francs in research and development. For more information about Roche in Germany, visit www.roche.de.

 

For more information and media inquiries, please contact:

 

Temedica GmbH

 

Anna Hauner

Corporate Communications

E-Mail: [email protected]

Tel: +49 175 4310301

 

 

Roche Pharma AG

 

Faten Gaber

Head of Communications & Public Affairs

Emil-Barell-Straße 1

79639 Grenzach-Wyhlen

[email protected]

Tel: +49 7624 14-4000